We have therefore used cases of sporadic gastric SRCCs in SEER to crudely estimate possible secondary cancer risks in our CDH1 mutation patients, recognizing that SRCCs comprise 10–18% of all gastric cancer cases whereas HDGC are fewer at 1–3% [15]. The gene discussed is CDH1; the disease is cancer.